



**HAL**  
open science

## Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic GVHD

Bronwen E Shaw, Jane Apperley, Nigel H Russell, Charles Craddock, Effie Liakopoulou, M Potter, Robert F Wynn, Brenda Gibson, Rachel M Pearce, Keiren Kirkland, et al.

### ► To cite this version:

Bronwen E Shaw, Jane Apperley, Nigel H Russell, Charles Craddock, Effie Liakopoulou, et al.. Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic GVHD. *British Journal of Haematology*, 2011, 153 (2), pp.244. 10.1111/j.1365-2141.2011.08615.x . hal-00620598

**HAL Id: hal-00620598**

**<https://hal.science/hal-00620598v1>**

Submitted on 8 Sep 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with any increased risk of significant acute or chronic GVHD**

Journal:	<i>British Journal of Haematology</i>
Manuscript ID:	BJH-2010-01775.R1
Manuscript Type:	Ordinary Papers
Date Submitted by the Author:	19-Jan-2011
Complete List of Authors:	Shaw, Bronwen; Royal Marsden Hospital, Haemato-Oncology Apperley, Jane; Department of Haematology RUSSELL, NIGEL; Nottingham City Hospital, Haematology Craddock, Charles; Leukaemia Unit, Department of Haematology Liakopoulou, Effie; Christie NHS FT, Haematology and Transplantation Potter, M; royal marsden hospital, haematology Wynn, Robert F; RMCH, Department of Haematology Gibson, Brenda; Royal Hospital for Sick Children, Dept of Haematology Pearce, Rachel; University College London, BSBMT KIRKLAND, KEIREN; BSBMT, HEAD OF DATA REGISTRY Lee, Julia; King's College Hospital, BSBMT Data Registry Madrigal, Alejandro; Anthony Nolan Research Institute, Royal Free Hospital Cook, Gordon; St James' Institute of Oncology, Haematology Byrne, Jennifer L; Nottingham University, Department of Haematology
Key Words:	TRANSPLANTATION, STEM CELLS, T CELL DEPLETION

1  
2  
3 Title: Unrelated donor peripheral blood stem cell transplants incorporating pre-  
4 transplant in-vivo Alemtuzumab are not associated with any increased risk  
5 of significant acute or chronic GVHD  
6

7  
8 Running title: Stem cell source in unrelated transplantation  
9

10 Authors: B E Shaw, MD <sup>1,2</sup>,  
11 J F Apperley, MD <sup>3</sup>,  
12 N H Russell, MD <sup>4</sup>,  
13 C Craddock, MD <sup>5</sup>,  
14 E Liakopoulou, MD <sup>6</sup>,  
15 M N Potter, MD <sup>2</sup>,  
16 R Wynn, MD <sup>7</sup>,  
17 B Gibson, MD <sup>8</sup>,  
18 R M Pearce, Msc <sup>9</sup>,  
19 K Kirkland, Msc <sup>9</sup>,  
20 J Lee, Msc <sup>9</sup>,  
21 J A Madrigal, MD <sup>1</sup>,  
22 G Cook, MD <sup>10</sup>,  
23 J L Byrne, MD <sup>4</sup>  
24  
25  
26  
27

28 Affiliations: <sup>1</sup>Anthony Nolan Trust, London,  
29 <sup>2</sup>Royal Marsden Hospital, London,  
30 <sup>3</sup>Imperial College, London,  
31 <sup>4</sup>Nottingham University Hospital (City Campus), Nottingham, <sup>5</sup>Queen  
32 Elizabeth Hospital, Birmingham,  
33 <sup>6</sup>Christie Hospital, Manchester,  
34 <sup>7</sup>Manchester Children's Hospital, Manchester,  
35 <sup>8</sup>Royal Hospital for Sick Children, Glasgow,  
36 <sup>9</sup>BSBMT, London,  
37 <sup>10</sup>St James's University Hospital, Leeds  
38  
39  
40

41 Corresponding author: Dr Bronwen Shaw  
42 The Anthony Nolan Research Institute  
43 Royal Free Hospital, Pond Street  
44 Hampstead, London  
45 NW3 2QG, UK  
46 Email: [bshaw@doctors.org.uk](mailto:bshaw@doctors.org.uk)  
47 Telephone: +442072848339  
48 Fax: +442072848331  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Key words: unrelated donor, T cell depletion, myeloablative, PBSC, BM  
4

5  
6 Word count: 3520  
7

8 Abstract: 196  
9

10 Figures: 4  
11

12 Tables: 2  
13

14  
15 References: 35  
16

17 Scientific category: Transplantation  
18

19 Authorship statement:  
20

21 JLB, NHR and BES contributed to the design and analysis. RP performed the statistical analysis.  
22 All authors contributed to the data collection, writing and review of the manuscript.  
23

24 None of the authors have any financial disclosures or conflicts of interest  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo Alemtuzumab are not associated with an increased risk of significant acute or chronic GVHD

B E Shaw, J F Apperley, N H Russell, C Craddock, E Liakopoulou, M N Potter, R Wynn, B Gibson, R Pearce, K Kirkland, J Lee, J A Madrigal, G Cook, J L Byrne

### Abstract

There is little information published on the long-term outcomes in recipients of T-cell depleted (TCD) unrelated donor (UD) transplants comparing Peripheral Blood Stem Cells (PBSC) with Bone Marrow (BM). We present retrospective outcome data on 306 recipients of myeloablative, HLA-matched UD allografts using pre-transplant in-vivo Alemtuzumab. Transplants were performed between 2000–2007 for CML (CP1) and acute leukaemia (CR1/2) and 184 patients received BM and 122 PBSC. The median age was 28.9 years (<1–58years) and the median follow-up was 48 months. Overall survival at 8 years is 53%. The incidence of acute GvHD was significantly higher in PBSC (65%) than BM recipients (49%;  $p=0.012$ ). This represented only grade 1 GVHD with no difference in grade II–IV aGvHD (BM 23% PBSC 24%). The incidence of chronic GvHD, either overall (BM 47%, PBSC 49%) or extensive (BM 15%, PBSC 13%) was not increased with PBSC. The incidence of relapse, non-relapse mortality and survival were not significantly different. Whilst accepting the limitations of retrospective analyses, we suggest the increased risk of GvHD in recipients of PBSC in T-replete transplants is offset by in-vivo Alemtuzumab, and that either stem cell source can be used with good outcomes in this setting.

### Introduction

The use of unrelated donors for allogeneic transplantation has extended the availability of this potentially life-saving therapy to those who lack a sibling donor. In view of the increased genetic disparity between recipient and donor the incidence of some complications, such as graft versus host disease (GvHD), are increased. Recent advances in technology, including those related to HLA-typing, have resulted in the outcome of UD transplants reaching that of transplants using sibling donors (Goldstone and Rowe 2009, Lee, *et al* 2009), in part due to a reduction in the incidence of severe GvHD. One highly successful strategy to reduce GvHD is the use of T cell depletion (TCD) - either *in vivo* or *ex vivo* (Kottaridis, *et al* 2000, Marks, *et al* 2000).

A commonly used method of in-vivo TCD is Alemtuzumab, given for several days pre-transplant. Alemtuzumab is an antibody against CD52 and as such depletes not only T-cells, but also other cell subset such as B cells and dendritic cells (Hale, *et al* 1998). Alemtuzumab has been shown to persist in the patient's circulation for up to 30 days post infusion, allowing for depletion of CD52-positive cells from the patient as well as from the donor cells on infusion (Rebello, *et al* 2001).

Historically all donors provided stem cells via a bone marrow (BM) harvest. Since the 1990s we have had the ability to collect GCSF-mobilised peripheral blood stem cells (PBSC) and since 2000 their use in UD has increased considerably (Ljungman, *et al* 2009). In view of the low incidence of significant short-term side effects and the ease of donation, approximately 70–80% of unrelated donors opt to donate via this method in preference to BM harvesting (Miller, *et al* 2008, Pulsipher, *et al* 2009). It was clear from early experience that the number of cells (CD34+

1  
2  
3 and CD3+ cells) harvested via PBSC was greater than that by BM harvesting (Pavletic, *et al*  
4 1998). While this was associated with a significantly shorter engraftment times, there were  
5 concerns that the incidence of GvHD would be increased with the use of PBSC. Indeed, a number  
6 of studies, predominantly in sibling transplants, showed an increased incidence of both acute  
7 and/or chronic GvHD in PBSC recipients (Schmitz, *et al* 2005, Schmitz, *et al* 2006, Storek, *et al*  
8 1997) without, however, an impact on patient outcome (Friedrichs, *et al* , Gallardo, *et al* 2009,  
9 Ringden, *et al* 2002, Schmitz, *et al* 2005). More recent studies have considered UD transplants  
10 (Blau, *et al* 2001, Eapen, *et al* 2007, Garderet, *et al* 2003, Remberger, *et al* 2005, Remberger, *et*  
11 *al* 2001), again confirming an increase in GvHD with PBSC, but not consistently showing any  
12 difference in outcome. Most of these studies, however include recipients of both HLA matched  
13 and mismatched grafts and all report series where transplants are predominantly T cell replete.  
14 A few studies have suggested a differential effect on survival due to stem cell source, both in  
15 sibling (Eapen, *et al* 2004, Group 2005) and UD transplants (Eapen, *et al* 2007, Garderet, *et al*  
16 2003). The large meta-analysis including 1111 adult recipients of HLA-identical sibling grafts  
17 (Group 2005), showed that PBSC was associated with increased incidences of both acute and  
18 chronic GvHD. However, PBSC was also associated with a decrease in relapse in both early and  
19 late stage disease, with a significantly improved survival in recipients of PBSC with late stage  
20 disease. Conversely, in a later study (Eapen, *et al* 2004) in children receiving HLA-identical  
21 sibling allografts, PBSC was associated with a higher incidence of chronic GvHD, as well as a  
22 worse overall survival and a higher transplant related mortality (TRM). Furthermore in a  
23 CIBMTR study of UD transplant outcome, Eapen *et al* (Eapen, *et al* 2007) showed a significantly  
24 higher incidence of both grade II-IV acute GvHD and of chronic GVHD. Although there was no  
25 detrimental effect on overall survival in the whole group, the subgroup of patients with chronic  
26 myeloid leukaemia (CML) in first chronic phase (CP1) receiving PBSC did have a significantly  
27 worse overall survival, with a trend to an increase in TRM. In the study by Garderet *et al*  
28 (Garderet, *et al* 2003), there was a trend to an increase in acute (but not chronic) GvHD in  
29 patients with ALL receiving PBSC, which was associated with an inferior survival compared to  
30 BM (without an impact on relapse).

31 We hypothesised that any negative impact caused by increased GvHD using PBSC compared to  
32 BM might be abrogated in recipients of UD transplants incorporating in-vivo Alemtuzumab  
33 conditioning for T cell depletion. Here we present data on the outcome in 306 UK transplant  
34 recipients with leukaemia studying the impact of stem cell source on outcome.  
35  
36

## 37 **Materials and methods**

### 38 **Data collection**

39 Patients fulfilling the requirements for this study were identified from the database held by the  
40 British Society for Blood and Marrow Transplantation (BSBMT) registry in London, UK. Data  
41 are reported at fixed time points in the form of the MED A and B forms derived from the  
42 European Group for Blood and Marrow Transplant (EBMT)). Data collected by the Anthony  
43 Nolan Trust from a previous study were added to the BSBMT database. 306 patients from 19  
44 centres were identified. Supplementary data requests were sent to all centres.  
45  
46

### 47 **Patients, definitions and inclusion criteria**

Criteria for inclusion were: 1. a transplant at a UK centre between 2000 and 2007. 2. myeloablative conditioning 3. in-vivo pre-transplant T cell depletion using alemtuzumab 4. HLA matched (10/10) unrelated donor 5. standard risk leukaemia (acute myeloid or lymphoblastic leukaemia in first or second complete remission (CR), CML in CP1).

HLA typing was performed in the local Histocompatibility and Immunogenetics laboratories by molecular methods to achieve high resolution types.

Alemtuzumab schedule and dose were given according to institutional protocols. Both the overall dosing and the days of infusion differed between institutions. However the dose of Alemtuzumab within an institution did not differ depending on whether the stem cell product was BM or PBSC. CMV was treated pre-emptively. Donor leukocyte infusions (DLI) were not used routinely, but given in some cases according to institutional protocols for mixed chimerism, relapse or viral reactivations.

Primary Graft Failure was defined as a failure to achieve a neutrophil count of  $0.5 \times 10^9/l$  by day 28 and was evaluable only in those surviving at least 28 days after the transplant. Relapses were defined as haematological, cytogenetic or molecular. Acute and chronic GvHD were defined using internationally accepted criteria.

The protocols used were approved by the individual institutional review boards of all of the contributing hospitals. Informed consent for the transfer of data to, and the analysis by, the BSBMT was obtained from all patients.

### Statistical analyses

Relationships between categorical variables were analysed by Fisher's exact test. Continuous variables such as age were tested using the k-sample equality of medians test. Overall survival was calculated by Kaplan-Meier analysis. Univariate analysis of OS and PFS was performed using the log-rank test, and multivariate analysis by Cox regression. Cumulative incidence of non-relapse mortality was calculated by competing risks regression, with death from relapse as the competing risk. Relapse rate was calculated as a cumulative incidence by competing risks regression, with transplant related death and chronic GvHD as the competing risks. Cumulative incidence of cGvHD was calculated by competing risks regression with death and relapse as competing risks. **All multivariate models were designed to include any factor which had a p value of <0.2 in univariate analysis plus the source of stem cells. In view of the relatively small dataset and number of significant variables, stepwise inclusion / exclusion were not applied.**

Statistics tests were performed using Stata (StataCorp, Texas 77845 URL: <http://www.stata.com>), with competing risks calculated using "stcompet" (Enzo Coviello, Italy; May Boggess, StataCorp); and using R (R Development Core Team (2006). R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL <http://www.R-project.org>), with competing risks calculated using the package "cmprsk" (RJ Gray).

### Results



### Patient and transplant characteristics

306 patients were included in the study. Patient, disease and transplant characteristics are presented in Table 1. The majority of conditioning regimens included TBI (92%), usually in combination with cyclophosphamide (84%), and additional GvHD prophylaxis with cyclosporine alone or cyclosporine and short-course methotrexate was used. In all patients T cell depletion was performed using pre-transplant in vivo Alemtuzumab. The two groups were similar, except for an increased use of BM in patients with CML ( $p=0.007$ ) and the disease stage differed significantly between the groups ( $p=0.001$ ). 24 patients received donor lymphocyte infusions (DLI) post-transplant, 17 for disease relapse, 2 for viral reactivations and 5 for mixed chimerism.

### Engraftment

1% (4/306) of patients had primary graft failure. Of these, 2 received BM and 2 received PBSC (two had a second allograft and are alive, while two succumbed from infection or disease progression, one each in the BM and PBSC groups). A further 4 patients who received BM had secondary graft failure (two of whom remain alive following further cellular therapy) while none of the PBSC recipients developed this complication. There was no statistically significant difference between stem cell sources in the incidence of graft failure overall ( $p=0.306$ ). The median time to neutrophil engraftment was 18 days (range: 9-61 days). This was significantly faster in recipients of PBSC (15 days) than BM (20 days,  $p<0.0001$ ). Likewise, platelet engraftment was significantly faster in recipients of PBSC (17 days) than BM (28 days,  $p<0.0001$ ), with a median of 24 days (5-469).

### Graft versus Host Disease (GvHD)

All patients who achieved neutrophil engraftment were considered eligible for analysis. The incidence of acute GvHD (aGvHD) of any grade, grade II-IV and grade III-IV were 56%, 23% and 4% respectively. There was a significantly higher risk of developing aGvHD in the recipients of PBSC (65%) compared to BM recipients (49%,  $p=0.012$ ), but this risk was only apparent in grade 1 disease. Most importantly, there were no significant differences in severe aGvHD between the groups (**grade III/IV: BM 4% PBSC 5%,  $p=0.554$** ) (Table 2). No other factor had a significant impact on the incidence or severity of aGvHD in either univariate or multivariate analysis.

Overall chronic GvHD (cGvHD) developed in 119/235 patients (48% at 5 years). There was no significant difference in the incidence of cGvHD dependant on stem cell source (5 years: 47% following BMT and 49% following PBSC;  $p=0.48$ ) (figure 1). Strikingly, extensive cGvHD occurred in only 15% of BM recipients and 13% of PBSC recipients ( $p=0.831$ ). Factors associated with cGvHD were CMV seropositivity in the patient (**Hazard ratio (HR) =1.56; Confidence interval (CI) 1.07 – 2.27,  $p=0.029$** ) and disease in CR1/CP1 (**HR 0.66; CI 0.43 - 1.00,  $p=0.054$** ). In multivariate analysis, including these two factors and source of stem cells and age, only disease status at transplant showed a trend towards significance (**HR=0.68; CI 0.44 – 1.05,  $p=0.081$** ).

### Non-relapse mortality (NRM)

NRM was 9% and 20% at day 100 and 1 year respectively (figure 2). There were no significant differences in NRM between recipients of BM or PBSC (day 100: 9% and 11%, 1 year: 20% and 20%, and 5 year: 23% and 25% respectively,  $p=0.77$ ). There was no significant impact on NRM



1  
2  
3 due to the presence or absence of aGvHD. Factors associated with NRM in univariate analysis  
4 were: patient CMV (HR 2.15; CI 1.34 – 3.47, p=0.001) and donor (HR 1.54; CI 0.93 – 2.53,  
5 p=0.090) CMV seropositivity. In multivariate analysis (including these factors, patient age and  
6 stem cell source) the only factor to remain significantly associated with a higher mortality was  
7 CMV seropositivity in the patient (HR=1.98; CI 1.16 – 3.38, p=0.012). The causes of NRM were:  
8 GvHD (22%), infection (62%) and other (16%), which did not differ significantly depending on  
9 stem cell source (p=0.358).  
10  
11

### 12 13 **Relapse**

14 The cumulative incidences of relapse were 36% and 41% at 2 and 5 years respectively (figure 3).  
15 Relapse was predominantly haematological in patients with acute leukaemia (86%), with 6%  
16 defined as cytogenetic and 8% defined as molecular. In contrast, only 41% of relapses in CML  
17 were haematological with 26% defined as cytogenetic and 33% defined as molecular. There was  
18 a trend to a difference in relapse rate according to whether the patient received BM or PBSC (5  
19 years: 45% and 33% respectively, p=0.096). The only factor to impact significantly on disease  
20 relapse was disease type, with a relapse risk of 58% at 5 years in CML patients compared to 33%  
21 in AL patients (p<0.001). There was a trend to an increase in relapse in CMV seronegative  
22 patients (HR=0.69; CI 0.46-1.04, p=0.075). There were no differences in relapse risk between  
23 patients with AL transplanted in CR1 or CR2 (both 33%). In multivariate analysis, including  
24 disease, patient and donor CMV and stem cell source, the only significant factor was the  
25 underlying disease (HR=2.03; CI 1.38-2.98, p<0.001). There was no significant impact on relapse  
26 due to the presence or absence of aGvHD.  
27  
28  
29  
30

### 31 **Survival**

32 The median follow up is 48 months (3-110 months). This was significantly longer in recipients of  
33 BM than PBSC (59 vs. 36 months, p=0.001) (figure 4). The overall survival in the whole group  
34 was 53% at 8 years, with progression free survival of 36% at the same time point. There were no  
35 significant differences in survival between patient who received BM or PBSC (8 years: 54% and  
36 52% respectively, p=0.571). Likewise progression free survival was similar (8 years: 32% and  
37 42% respectively, p=0.225). There was no significant impact on OS due to the presence or  
38 absence of aGvHD. Two factors were significantly associated with an improved survival in  
39 univariate analysis: CML compared to AL (p=0.005) and CMV seronegativity in patients  
40 (p=0.025). Both of these factors remained significant in multivariate analysis (HR 0.57; CI 0.37-  
41 0.86, p=0.010 and HR 0.70; CI 0.49-0.99, p=0.046 respectively), while PBSC vs. BM was not  
42 significant (HR 1.03; CI 0.73 – 1.49, p=0.826).  
43  
44  
45

### 46 **Discussion**

47  
48 This study is the first to consider the impact of stem cell source in a cohort of in-vivo T cell  
49 depleted HLA matched UD allograft recipients. In contrast to previous studies of T-replete UD  
50 transplants, we show no increase in the risk of grade II-IV acute GVHD or of chronic GVHD in  
51 recipients of PBSC. The only significant difference between BM and PBSC recipients in this  
52 study was a higher incidence of grade I aGvHD in the PBSC group.  
53  
54

55  
56 In 617 adult recipients of T cell replete UD transplants, Eapen et al (Eapen, *et al* 2007) reported  
57 an increase in the incidence of overall, but not grade III/IV, aGvHD with PBSC. In addition,  
58  
59  
60

1  
2  
3 unlike our report, the incidence of cGvHD was also found to be significantly higher in the  
4 patients receiving PBSC. Two smaller studies by Garderet *et al* (Garderet, *et al* 2003) (n=213)  
5 and Blau *et al* (Blau, *et al* 2001) (n=74) reported significant increases in aGvHD (only in HLA  
6 mismatched patients in the latter study), but no increase in cGvHD. In two studies by Remberger  
7 *et al*, reporting on both short (Remberger, *et al* 2001) and long term (Remberger, *et al* 2005)  
8 follow-up in 214 adult transplant recipients, there was no increase in aGvHD while the incidence  
9 of chronic extensive GvHD was significantly higher when PBSC was used compared to BM.  
10  
11

12  
13 There are a number of clear differences between these studies, the most important being the use  
14 or not of T-cell depletion, in particular, Alemtuzumab. A possible additional factor explaining the  
15 lack of impact of stem cell source on cGvHD is the differing length of follow-up in each study.  
16 The median follow-up in the Remberger study is over 4 years (which is the same as in our current  
17 study), while that in the other studies ranges between 1.5 and 3 years and, in some, differs  
18 between the PBSC and BM groups. The pattern of GvHD may also be of interest. All of the  
19 studies to date report outcomes using the 'old' classification of GvHD i.e. using a simply time cut  
20 off between acute and chronic. It may be that using the reclassification of GvHD in future  
21 studies, would provide further insights (Filipovich 2008). In our study we noticed that the time to  
22 onset of cGVHD was shorter in the PBSC than the BM group (data not shown), suggesting that a  
23 proportion of the 'chronic' GvHD would now be reclassified as late onset acute or persistent  
24 rather than de novo chronic GvHD. It is well recognised that chronic GvHD is more likely in  
25 patients who have suffered acute GvHD (especially of higher grades) which may explain the  
26 increase in cGvHD in the Eapen study (where the incidence of acute GvHD was higher than in  
27 our study), while this may be less discernable in the Blau and Garderet study where the overall  
28 and grade II/IV aGvHD incidence was less.  
29  
30  
31

32  
33 T cell depletion using Alemtuzumab was universal in our study. This method of GvHD  
34 prophylaxis was either absent or used in a very small minority of patients in the other studies  
35 except for the Remberger study where one third of patients received ATG. Direct comparisons  
36 between ATG and Alemtuzumab cannot be made given that Alemtuzumab depletes all CD52-  
37 positive cells and not just T cells. The use of ATG in only a proportion of patients and the  
38 likelihood of 'hidden' HLA mismatches in that study, especially for HLA-C (low resolution  
39 HLA-A and -B and high resolution -DRB1 matching criteria were used) may account for the  
40 high incidence of chronic GvHD that they observed. All of the recipients included in our study  
41 had high resolution typing performed.  
42  
43  
44

45 The significant reduction in overall incidence of GvHD following TCD strategies (in particular  
46 grade III-IV acute and extensive chronic) compared to that following T cell replete  
47 transplantation has been reported in both randomised (Bacigalupo, *et al* 2006, Bacigalupo, *et al*  
48 2001, Finke, *et al* 2009, Wagner, *et al* 2005) as well as non-randomised studies (Chakraverty, *et al*  
49 2002, Craddock, *et al* 2009, Kennedy-Nasser, *et al* 2008, Kottaridis, *et al* 2000, Malladi, *et al*  
50 2009, Mohty, *et al* 2003). Conversely, both infection (Bacigalupo, *et al* 2001, Malladi, *et al*  
51 2009) and relapse (Wagner, *et al* 2005) may be increased in the TCD setting, due to delayed  
52 immune reconstitution and a reduced graft versus leukaemia effect. In this study CMV  
53 seropositivity in the recipient was associated with an inferior survival. It is well recognised that  
54 CMV reactivation is common following TCD (Finke, *et al* 2009, Wagner, *et al* 2005). Although  
55 the direct impact of CMV reactivation on mortality is minimal due to pre-emptive strategies, it is  
56  
57  
58  
59  
60

1  
2  
3 known that CMV seropositivity is associated with a predisposition to other infections and may  
4 impact on survival in other less well defined ways (Craddock, *et al* 2001, Nichols, *et al* 2002).  
5 Although the relapse risk in the AL patients in this study was acceptable, the relapse risk in CML  
6 was disappointingly high (although not significantly different based on stem cell source). This  
7 may be due to the inclusion of TCD in the conditioning as previously reported (Wagner, *et al*  
8 2005).  
9  
10

11 Neither our or other UD studies have reported any significant differences due to stem cell source  
12 in TRM, relapse or OS in the overall group studied. In the Eapen study there was a trend to a  
13 higher TRM, with a significantly lower OS, in recipients with CML in CP1, although the reason  
14 for this is not clear. In the Gardaret study patients with ALL receiving PBSC had a significantly  
15 lower DFS and OS. Besides the obvious differences with regards to TCD, other differences  
16 between the studies are noted, such as the inclusion of both paediatric and adult patients, the  
17 degree of HLA matching, the diseases and stage of disease included, medical GvHD prophylaxis  
18 and the year of transplantation. None of the studies in UDs are randomised and the results of the  
19 BMT CTN 0201 randomised trial (Peripheral Blood versus Bone Marrow Grafts from Unrelated  
20 Donors) ([http://www.cibmtr.org/Studies/ClinicalTrials/BMT\\_CTN/Protocols/0201/index.html](http://www.cibmtr.org/Studies/ClinicalTrials/BMT_CTN/Protocols/0201/index.html))  
21 are keenly awaited.  
22  
23  
24

25 It is recognised that the current study has a number of limitations. In common with most  
26 retrospective studies there is some heterogeneity in the study group. Although TCD using  
27 Alemtuzumab was universal, the schedule and dosage varied between centres. Importantly,  
28 however, the dose of Alemtuzumab within an institution did not differ depending on whether the  
29 stem cell product was BM or PBSC. In addition the use of cyclosporin (with or without  
30 methotrexate) differed by centre. DLI were given for various reasons, but none as part of a  
31 planned immunotherapy program. Any impact of DLI on outcomes should be negligible, as most  
32 were given for relapse, and this was taken into account as a competing risk for chronic GVHD.  
33 Although the number of CD34+ cells is known, the data on CD3+ and other cell subset content of  
34 the graft were not available.  
35  
36  
37  
38

39 In conclusion, in this study we confirm the low incidence of severe GvHD following TCD  
40 myeloablative transplantation from UD for patients with standard risk leukaemia, with excellent  
41 long-term survival rates. The use of either BM or PBSC was associated with equally good  
42 outcomes. The only significant difference between the groups was an increase in grade 1 acute  
43 GvHD in the PBSC recipients. The risk of extensive cGVHD was low and did not differ with  
44 stem cell source. These data suggest that either stem cell source can be used with equivalent  
45 results and that there is no deleterious effect from the use of PBSC in Alemtuzumab containing  
46 unrelated donor transplants.  
47  
48

## 49 **Acknowledgements**

50 We would like to thank all of the UK transplant teams who have contributed patients to this  
51 study.  
52  
53  
54

## 55 **Contributors**

CIC: Hospital: Transplant lead: data manager

205: Hammersmith Hospital: Prof Jane Apperley: Priscilla Plocki  
 717: Nottingham University Hospital (City Campus): Prof Nigel Russell: Pam Nelson  
 387: Queen Elizabeth Hospital Birmingham: Prof Charles Craddock: Janice Ward  
 780: Christie's Manchester: Dr Effie Liakopoulou: Thomas Dalton  
 218: Royal Marsden Hospital: Dr Mike Potter: Helena Woods  
 521: Manchester Children's Hospital: Dr Robert Wynn: Mary Coussons  
 707: Royal Hospital for Sick Children, Glasgow: Dr Brenda Gibson: Graham Stewart  
 501: Royal Hospital Liverpool: Dr Richard Clark: Lynne Laing  
 254: St James's University Hospital Leeds: Dr Gordon Cook: Rachel Goodall/Karen Benn  
 778: Royal Hallamshire Hospital, Sheffield: Dr John Snowden: Barbara Holt  
 303: Cardiff: Dr Keith Wilson: Sandra Nicholas  
 276: Newcastle University Hospital: Dr Graham Jackson: Linda McNally  
 284: Heartlands, Birmingham: Dr Don Milligan: James Whitehouse  
 713: Leicester Royal Infirmary: Dr Ann Hunter: Rik Lewin  
 539: St George's Hospital, London: Prof Edward Gordon-Smith: Preeti Datta-Nemdharry  
 566: Addenbrooke's Hospital, Cambridge: Dr Charles Crawley: Debra Tournant  
 243: Great Ormond Street Hospital: Dr Paul Veys: Kamil Sanaullah  
 263: The London Clinic: Dr Mike Potter: Anjaya Taylor  
 866: St Mary's Hospital: Dr Josu De La Fuente: Farah O'boyle

**Authorship contributions**

JLB, NHR and BES contributed to the design and analysis. RP performed the statistical analysis. All authors contributed to the data collection, writing and review of the manuscript.

**Conflict of Interest**

There are no conflicts of interest to disclose for any of the authors.

**References**

- Bacigalupo, A., Lamparelli, T., Barisione, G., Bruzzi, P., Guidi, S., Alessandrino, P.E., di Bartolomeo, P., Oneto, R., Bruno, B., Sacchi, N., van Lint, M.T. & Bosi, A. (2006) Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. *Biology of Blood and Marrow Transplantation*, **12**, 560-565.
- Bacigalupo, A., Lamparelli, T., Bruzzi, P., Guidi, S., Alessandrino, P.E., di Bartolomeo, P., Oneto, R., Bruno, B., Barbanti, M., Sacchi, N., Van Lint, M.T. & Bosi, A. (2001) Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). *Blood*, **98**, 2942-2947.
- Blau, I.W., Basara, N., Lentini, G., Guenzelmann, S., Kirsten, D., Schmetzer, B., Bischoff, M., Roemer, E., Kiehl, M.G. & Fauser, A.A. (2001) Feasibility and safety of peripheral blood stem cell transplantation from unrelated donors: results of a single-center study. *Bone Marrow Transplantation*, **27**, 27-33.

- 1  
2  
3 Chakraverty, R., Peggs, K., Chopra, R., Milligan, D.W., Kottaridis, P.D., Verfuert, S., Geary, J.,  
4 Thurai Sundaram, D., Branson, K., Chakrabarti, S., Mahendra, P., Craddock, C., Parker,  
5 A., Hunter, A., Hale, G., Waldmann, H., Williams, C.D., Yong, K., Linch, D.C.,  
6 Goldstone, A.H. & Mackinnon, S. (2002) Limiting transplantation-related mortality  
7 following unrelated donor stem cell transplantation by using a nonmyeloablative  
8 conditioning regimen. *Blood*, **99**, 1071-1078.
- 9  
10 Craddock, C., Nagra, S., Peniket, A., Brookes, C., Buckley, L., Nikolousis, E., Duncan, N.,  
11 Tauro, S., Yin, J., Liakopoulou, E., Kottaridis, P., Snowden, J., Milligan, D., Cook, G.,  
12 Tholouli, E., Littlewood, T., Peggs, K., Vyas, P., Clark, F., Cook, M., Mackinnon, S. &  
13 Russell, N. (2010) Factors Predicting Long Term Survival After T Cell Depleted Reduced  
14 Intensity Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia.  
15 *Haematologica*, **95**, 989-9.
- 16  
17 Craddock, C., Szydlo, R.M., Dazzi, F., Olavarria, E., Cwynarski, K., Yong, A., Brookes, P., de la  
18 Fuente, J., Kanfer, E., Apperley, J.F. & Goldman, J.M. (2001) Cytomegalovirus  
19 seropositivity adversely influences outcome after T-depleted unrelated donor transplant in  
20 patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease  
21 prophylaxis. *British Journal of Haematology*, **112**, 228-236.
- 22  
23 Eapen, M., Horowitz, M.M., Klein, J.P., Champlin, R.E., Loberiza, F.R., Jr., Ringden, O. &  
24 Wagner, J.E. (2004) Higher mortality after allogeneic peripheral-blood transplantation  
25 compared with bone marrow in children and adolescents: the Histocompatibility and  
26 Alternate Stem Cell Source Working Committee of the International Bone Marrow  
27 Transplant Registry. *Journal of Clinical Oncology*, **22**, 4872-4880.
- 28  
29 Eapen, M., Logan, B.R., Confer, D.L., Haagenson, M., Wagner, J.E., Weisdorf, D.J., Wingard,  
30 J.R., Rowley, S.D., Stroncek, D., Gee, A.P., Horowitz, M.M. & Anasetti, C. (2007)  
31 Peripheral blood grafts from unrelated donors are associated with increased acute and  
32 chronic graft-versus-host disease without improved survival. *Biology of Blood Marrow  
33 Transplantation*, **13**, 1461-1468.
- 34  
35 Filipovich, A.H. (2008) Diagnosis and manifestations of chronic graft-versus-host disease. *Best  
36 Practical Research in Clinical Haematology*, **21**, 251-257.
- 37  
38 Finke, J., Bethge, W.A., Schmoor, C., Ottinger, H.D., Stelljes, M., Zander, A.R., Volin, L.,  
39 Ruutu, T., Heim, D.A., Schwerdtfeger, R., Kolbe, K., Mayer, J., Maertens, J.A., Linkesch,  
40 W., Holler, E., Koza, V., Bornhauser, M., Einsele, H., Kolb, H.J., Bertz, H., Egger, M.,  
41 Grishina, O. & Socie, G. (2009) Standard graft-versus-host disease prophylaxis with or  
42 without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated  
43 donors: a randomised, open-label, multicentre phase 3 trial. *Lancet Oncology*, **10**, 855-  
44 864.
- 45  
46 Friedrichs, B., Tichelli, A., Bacigalupo, A., Russell, N.H., Ruutu, T., Shapira, M.Y., Beksac, M.,  
47 Hasenclever, D., Socie, G. & Schmitz, N. Long-term outcome and late effects in patients  
48 transplanted with mobilised blood or bone marrow: a randomised trial. *Lancet Oncology*,  
49 **11**, 331-338.
- 50  
51 Gallardo, D., de la Camara, R., Nieto, J.B., Espigado, I., Iriondo, A., Jimenez-Velasco, A.,  
52 Vallejo, C., Martin, C., Caballero, D., Brunet, S., Serrano, D., Solano, C., Ribera, J.M., de  
53 la Rubia, J. & Carreras, E. (2009) Is mobilized peripheral blood comparable with bone  
54 marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-  
55 identical sibling donors? A case-control study. *Haematologica*, **94**, 1282-1288.
- 56  
57 Garderet, L., Labopin, M., Gorin, N.C., Polge, E., Fouillard, L., Ehninger, G.E., Ringden, O.,  
58  
59  
60



- 1  
2  
3 Finke, J., Tura, S. & Frassoni, F. (2003) Patients with acute lymphoblastic leukaemia  
4 allografted with a matched unrelated donor may have a lower survival with a peripheral  
5 blood stem cell graft compared to bone marrow. *Bone Marrow Transplantation*, **31**, 23-  
6 29.  
7
- 8 Goldstone, A.H. & Rowe, J.M. (2009) Transplantation in adult ALL. *Hematology American*  
9 *Society Hematology Educational Program*, 593-601.  
10
- 11 Group, S.C.T.C. (2005) Allogeneic peripheral blood stem-cell compared with bone marrow  
12 transplantation in the management of hematologic malignancies: an individual patient  
13 data meta-analysis of nine randomized trials. *Journal of Clinical Oncology*, **23**, 5074-  
14 5087.  
15
- 16 Hale, G., Zhang, M.J., Bunjes, D., Prentice, H.G., Spence, D., Horowitz, M.M., Barrett, A.J. &  
17 Waldmann, H. (1998) Improving the outcome of bone marrow transplantation by using  
18 CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection.  
19 *Blood*, **92**, 4581-4590.  
20
- 21 Kennedy-Nasser, A.A., Bollard, C.M., Myers, G.D., Leung, K.S., Gottschalk, S., Zhang, Y., Liu,  
22 H., Heslop, H.E., Brenner, M.K. & Krance, R.A. (2008) Comparable outcome of  
23 alternative donor and matched sibling donor hematopoietic stem cell transplant for  
24 children with acute lymphoblastic leukemia in first or second remission using  
25 alemtuzumab in a myeloablative conditioning regimen. *Biology of Blood and Marrow*  
26 *Transplantation*, **14**, 1245-1252.  
27
- 28 Kottaridis, P.D., Milligan, D.W., Chopra, R., Chakraverty, R.K., Chakrabarti, S., Robinson, S.,  
29 Peggs, K., Verfuether, S., Pettengell, R., Marsh, J.C., Schey, S., Mahendra, P., Morgan,  
30 G.J., Hale, G., Waldmann, H., de Elvira, M.C., Williams, C.D., Devereux, S., Linch,  
31 D.C., Goldstone, A.H. & Mackinnon, S. (2000) In vivo CAMPATH-1H prevents graft-  
32 versus-host disease following nonmyeloablative stem cell transplantation. *Blood*, **96**,  
33 2419-2425.  
34
- 35 Lee, D.H., Kwon, Y.J., Lim, J., Kim, Y., Han, K., Chung, N.G., Jeong, D.C., Cho, B. & Kim,  
36 H.K. (2009) Comparable outcomes of HLA-matched unrelated and HLA-identical sibling  
37 donor bone marrow transplantation for childhood acute myeloid leukemia in first  
38 remission. *Pediatric Transplantation*, **13**, 210-216.  
39
- 40 Ljungman, P., Bregni, M., Brune, M., Cornelissen, J., Witte, T.D., Dini, G., Einsele, H., Gaspar,  
41 H.B., Gratwohl, A., Passweg, J., Peters, C., Rocha, V., Saccardi, R., Schouten, H.,  
42 Sureda, A., Tichelli, A., Velardi, A. & Niederwieser, D. (2009) Allogeneic and  
43 autologous transplantation for haematological diseases, solid tumours and immune  
44 disorders: current practice in Europe 2009. *Bone Marrow Transplantation*, **45**, 219-3.  
45
- 46 Malladi, R.K., Peniket, A.J., Littlewood, T.J., Towlson, K.E., Pearce, R., Yin, J., Cavenagh, J.D.,  
47 Craddock, C., Orchard, K.H., Olavarria, E., McQuaker, G., Collin, M. & Marks, D.I.  
48 (2009) Alemtuzumab markedly reduces chronic GVHD without affecting overall survival  
49 in reduced-intensity conditioning sibling allo-SCT for adults with AML. *Bone Marrow*  
50 *Transplantation*, **43**, 709-715.  
51
- 52 Marks, D.I., Bird, J.M., Vettenranta, K., Hunt, L., Green, A., Cornish, J.M., Goulden, N.,  
53 Pamphilon, D.H., Steward, C.G. & Oakhill, A. (2000) T cell-depleted unrelated donor  
54 bone marrow transplantation for acute myeloid leukemia. *Biology of Blood and Marrow*  
55 *Transplantation*, **6**, 646-653.  
56
- 57 Miller, J.P., Perry, E.H., Price, T.H., Bolan, C.D., Jr., Karanes, C., Boyd, T.M., Chitphakdithai,  
58 P. & King, R.J. (2008) Recovery and safety profiles of marrow and PBSC donors:  
59  
60

- 1  
2  
3 experience of the National Marrow Donor Program. *Biology of Blood and Marrow*  
4 *Transplantation*, **14**, 29-36.
- 5  
6 Mohty, M., Bay, J.O., Faucher, C., Choufi, B., Bilger, K., Tournilhac, O., Vey, N., Stoppa, A.M.,  
7 Coso, D., Chabannon, C., Viens, P., Maraninchi, D. & Blaise, D. (2003) Graft-versus-host  
8 disease following allogeneic transplantation from HLA-identical sibling with  
9 antithymocyte globulin-based reduced-intensity preparative regimen. *Blood*, **102**, 470-  
10 476.
- 11  
12 Nichols, W.G., Corey, L., Gooley, T., Davis, C. & Boeckh, M. (2002) High risk of death due to  
13 bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of  
14 stem cell transplants from seropositive donors: evidence for indirect effects of primary  
15 CMV infection. *Journal of Infectious Disease*, **185**, 273-282.
- 16  
17 Pavletic, Z.S., Joshi, S.S., Pirruccello, S.J., Tarantolo, S.R., Kollath, J., Reed, E.C., Bierman, P.J.,  
18 Vose, J.M., Warkentin, P.I., Gross, T.G., Nasrati, K., Armitage, J.O., Kessinger, A. &  
19 Bishop, M.R. (1998) Lymphocyte reconstitution after allogeneic blood stem cell  
20 transplantation for hematologic malignancies. *Bone Marrow Transplantation*, **21**, 33-41.
- 21  
22 Pulsipher, M.A., Chitphakdithai, P., Miller, J.P., Logan, B.R., King, R.J., Rizzo, J.D., Leitman,  
23 S.F., Anderlini, P., Haagenson, M.D., Kurian, S., Klein, J.P., Horowitz, M.M. & Confer,  
24 D.L. (2009) Adverse events among 2408 unrelated donors of peripheral blood stem cells:  
25 results of a prospective trial from the National Marrow Donor Program. *Blood*, **113**, 3604-  
26 3611.
- 27  
28 Rebello, P., Cwynarski, K., Varughese, M., Eades, A., Apperley, J.F. & Hale, G. (2001)  
29 Pharmacokinetics of CAMPATH-1H in BMT patients. *Cytotherapy*, **3**, 261-267.
- 30  
31 Remberger, M., Beelen, D.W., Fauser, A., Basara, N., Basu, O. & Ringden, O. (2005) Increased  
32 risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem  
33 cell transplantation using unrelated donors. *Blood*, **105**, 548-551.
- 34  
35 Remberger, M., Ringden, O., Blau, I.W., Ottinger, H., Kremens, B., Kiehl, M.G., Aschan, J.,  
36 Beelen, D.W., Basara, N., Kumlien, G., Fauser, A.A. & Runde, V. (2001) No difference  
37 in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone  
38 marrow using unrelated donors. *Blood*, **98**, 1739-1745.
- 39  
40 Ringden, O., Labopin, M., Bacigalupo, A., Arcese, W., Schaefer, U.W., Willemze, R., Koc, H.,  
41 Bunjes, D., Gluckman, E., Rocha, V., Schattenberg, A. & Frassoni, F. (2002)  
42 Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-  
43 identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic  
44 leukemia. *Journal of Clinical Oncology*, **20**, 4655-4664.
- 45  
46 Schmitz, N., Beksac, M., Bacigalupo, A., Ruutu, T., Nagler, A., Gluckman, E., Russell, N.,  
47 Apperley, J., Szerm, J., Bradstock, K., Buzyn, A., Schlegelberger, B., Matcham, J. &  
48 Gratwohl, A. (2005) Filgrastim-mobilized peripheral blood progenitor cells versus bone  
49 marrow transplantation for treating leukemia: 3-year results from the EBMT randomized  
50 trial. *Haematologica*, **90**, 643-648.
- 51  
52 Schmitz, N., Eapen, M., Horowitz, M.M., Zhang, M.J., Klein, J.P., Rizzo, J.D., Loberiza, F.R.,  
53 Gratwohl, A. & Champlin, R.E. (2006) Long-term outcome of patients given transplants  
54 of mobilized blood or bone marrow: A report from the International Bone Marrow  
55 Transplant Registry and the European Group for Blood and Marrow Transplantation.  
56 *Blood*, **108**, 4288-4290.
- 57  
58 Storek, J., Gooley, T., Siadak, M., Bensinger, W.I., Maloney, D.G., Chauncey, T.R., Flowers, M.,  
59 Sullivan, K.M., Witherspoon, R.P., Rowley, S.D., Hansen, J.A., Storb, R. & Appelbaum,  
60



1  
2  
3 F.R. (1997) Allogeneic peripheral blood stem cell transplantation may be associated with  
4 a high risk of chronic graft-versus-host disease. *Blood*, **90**, 4705-4709.

5  
6 Wagner, J.E., Thompson, J.S., Carter, S.L. & Kernan, N.A. (2005) Effect of graft-versus-host  
7 disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone  
8 marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. *Lancet*, **366**,  
9 733-741.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review

Table 1: Patient and donor demographics

Variable	BM (n=184)	PBSC (n=122)	P value
Year of transplant (median)	September 2002	February 2005	<0.001
Patient age (median, range)	28 (1-54)	30 (<1-58)	0.426
Patient gender			
Male	114 (62%)	73 (60%)	0.721
Female	70 (38%)	49 (40%)	
Donor/patient gender			
Donor M, recipient M	83 (49%)	57 (48%)	0.497
Donor M, recipient F	48 (28%)	30 (25%)	
Donor F, recipient M	22 (13%)	13 (11%)	
Donor F, recipient F	18 (11%)	18 (16%)	
Unknown	13	4	
Conditioning regimen			
TBI/Cy	158 (86%)	99 (83%)	0.439
TBI/other agent	11 (7%)	12 (9%)	
BuCy	14 (8%)	6 (5%)	
Other	1 (<1%)	5 (3%)	
Donor/patient CMV status			
Donor pos, recipient neg	23 (13%)	8 (7%)	0.273
Donor pos, recipient pos	29 (17%)	18 (16%)	
Donor neg, recipient neg	93 (53%)	63 (55%)	
Donor neg, recipient pos	29 (17%)	26 (23%)	
Unknown	10	7	
Diagnosis			
ALL	65 (35%)	46 (38%)	0.007
AML	53 (29%)	52 (43%)	
CML	66 (36%)	24 (20%)	
Stage			
AL: CR1	62 (34%)	64 (52%)	0.001
AL: CR2	55 (30%)	34 (28%)	
CML: CP1	67 (36%)	24 (20%)	
CD34+ cell dose (median, range)	2.91 (0.24 – 21.6)	5.83 (0.77 – 27.4)	<0.001

M – male, F - female, TBI – total body irradiation, Cy – cyclophosphamide, Bu – busulphan, AML – acute myeloid leukaemia, ALL - acute lymphoblastic leukaemia, CML – chronic myeloid leukaemia, AL – acute leukaemia, CR – complete remission, CP – chronic phase

Table 2: Incidence of acute GvHD comparing PBSC to BM.

Acute GvHD	BM	PBSC	P value
Present	87 (49%)	77 (65%)	0.012
Grade I	46 (26%)	48 (40%)	0.554*
Grade II	33 (19%)	23 (19%)	
Grade III	5 (3%)	4 (3%)	
Grade IV	1 (1%)	2 (2%)	
Unknown grade	2	0	

\*Refers to the lack of statistical significance between those with grade III/IV acute GvHD in the BM and PBSC group (i.e grade III/IV vs 0-II).

1  
2  
3 Figure legends:  
4  
5  
6

7 Figure 1: The incidence of cGvHD using either PBSC or BM. This did not differ significantly  
8 dependent on stem cell source.  
9

10  
11 Figure 2: Non-relapse mortality using either PBSC or BM.  
12

13  
14 Figure 3: The incidence of relapse using either PBSC or BM  
15  
16

17  
18 Figure 4: Overall survival in the study cohort dependent on the use of PBSC or BM. No  
19 significant difference was seen.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1




Figure 2





Figure 3





1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 4

